Nelly Firmin

1.8k total citations
51 papers, 446 citations indexed

About

Nelly Firmin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Nelly Firmin has authored 51 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Nelly Firmin's work include Sarcoma Diagnosis and Treatment (23 papers), Vascular Tumors and Angiosarcomas (11 papers) and Cardiac tumors and thrombi (7 papers). Nelly Firmin is often cited by papers focused on Sarcoma Diagnosis and Treatment (23 papers), Vascular Tumors and Angiosarcomas (11 papers) and Cardiac tumors and thrombi (7 papers). Nelly Firmin collaborates with scholars based in France, United States and Taiwan. Nelly Firmin's co-authors include William Jacot, Amélie Darlix, Simon Thézenas, Gilles Romieu, Séverine Guiu, Pierre‐Jean Lamy, Véronique D’Hondt, Evelyne Lopez‐Crapez, Pierre-Étienne Heudel and Elvire Pons‐Tostivint and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Nelly Firmin

47 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nelly Firmin France	11	237	235	93	84	81	51	446
Megan Kruse United States	11	175 0.7×	248 1.1×	58 0.6×	113 1.3×	144 1.8×	30	444
Irene De Santo Italy	9	342 1.4×	394 1.7×	169 1.8×	69 0.8×	213 2.6×	13	692
Abha Soni United States	10	139 0.6×	290 1.2×	134 1.4×	61 0.7×	107 1.3×	23	519
Dimitrios Krikelis Greece	13	152 0.6×	227 1.0×	167 1.8×	86 1.0×	103 1.3×	21	441
Zebing Liu China	13	134 0.6×	190 0.8×	249 2.7×	113 1.3×	125 1.5×	38	514
Michelle Ferreira United States	6	92 0.4×	383 1.6×	80 0.9×	32 0.4×	46 0.6×	13	570
Seiki Takashima Japan	12	216 0.9×	261 1.1×	52 0.6×	43 0.5×	85 1.0×	37	470
Silvia Ursino Italy	12	151 0.6×	188 0.8×	168 1.8×	32 0.4×	96 1.2×	23	528
Silvia Gisfredi Italy	14	169 0.7×	219 0.9×	241 2.6×	30 0.4×	117 1.4×	25	598
Kunio Araki Japan	15	198 0.8×	215 0.9×	227 2.4×	47 0.6×	139 1.7×	36	599

Countries citing papers authored by Nelly Firmin

Since Specialization

Citations

This map shows the geographic impact of Nelly Firmin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nelly Firmin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nelly Firmin more than expected).

Fields of papers citing papers by Nelly Firmin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nelly Firmin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nelly Firmin. The network helps show where Nelly Firmin may publish in the future.

Co-authorship network of co-authors of Nelly Firmin

This figure shows the co-authorship network connecting the top 25 collaborators of Nelly Firmin. A scholar is included among the top collaborators of Nelly Firmin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nelly Firmin. Nelly Firmin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Penel, Nicolas, Antoîne Italiano, Jennifer Wallet, et al.. (2025). Regorafenib as maintenance therapy after first-line doxorubicin-based chemotherapy in advanced non-adipocytic soft tissue sarcomas patients: a double-blind randomised trial. Annals of Oncology. 36(8). 944–953.

Jacot, William, Marie‐Christine Chateau, Simon Thézenas, et al.. (2025). Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers. Cancer Medicine. 14(5). e70615–e70615. 3 indexed citations

Sargos, Paul, M.-P. Sunyach, Anne Ducassou, et al.. (2025). Results of a phase Ib study of olaparib with concomitant radiotherapy in soft-tissue sarcoma: a French sarcoma group study. Annals of Oncology. 36(5). 592–600. 1 indexed citations

Llacer-Moscardo, C., L. Ollivier, Sylvie Helfré, et al.. (2024). Management of oligometastatic/metastatic sarcomas and place of local treatments with focus on modern radiotherapy approaches. Cancer/Radiothérapie. 28(1). 93–102. 2 indexed citations

Wallet, Jennifer, L. Chaigneau, Nelly Firmin, et al.. (2024). 1718O EREMISS trial: A double-blind placebo (PBO)-controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts). Annals of Oncology. 35. S1030–S1030. 1 indexed citations

Pautier, Patricia, Antoîne Italiano, Sophie Piperno‐Neumann, et al.. (2024). Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. New England Journal of Medicine. 391(9). 789–799. 29 indexed citations

Cesne, Axel Le, Christine Chevreau, Christophe Perrin, et al.. (2023). Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study. ESMO Open. 8(3). 101569–101569. 9 indexed citations

Brahmi, Mehdi, Olivier Trédan, Nicolas Penel, et al.. (2023). Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.. Journal of Clinical Oncology. 41(16_suppl). 11545–11545. 1 indexed citations

Leenhardt, Fanny, Frédéric Fiteni, Séverine Guiu, et al.. (2022). Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects. Pharmaceutics. 14(4). 841–841. 9 indexed citations

10.

Chen, Tom Wei‐Wu, A. Le Cesne, Antoîne Italiano, et al.. (2022). Soft tissue sarcoma incidences and clinical characteristics are significantly different in France and Taiwan. Cancer. 128(18). 3360–3369. 3 indexed citations

11.

Cohen, Sarah, Aude Guénolé, Ikrame Lazar, et al.. (2022). A POLD3/BLM dependent pathway handles DSBs in transcribed chromatin upon excessive RNA:DNA hybrid accumulation. Nature Communications. 13(1). 2012–2012. 23 indexed citations

12.

Firmin, Nelly, Célia Touraine, Angélique Chapelle, et al.. (2021). A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy. Nutrients. 13(12). 4429–4429. 5 indexed citations

13.

Boudou‐Rouquette, Pascaline, E. Martin, Emmanuelle Kempf, et al.. (2021). Rare bone sarcomas: A retrospective analysis of 145 adult patients from the French Sarcoma Group. International Journal of Cancer. 150(5). 825–836. 1 indexed citations

14.

Aldea, Mihaela, Sophie Piperno‐Neumann, Nelly Firmin, et al.. (2021). Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group. International Journal of Cancer. 150(4). 645–653. 10 indexed citations

15.

Cissé, Madi Y., Nelly Firmin, Maud Heuillet, et al.. (2020). Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma. Science Translational Medicine. 12(547). 29 indexed citations

16.

Maran-Gonzalez, Aurélie, Marie Viala, Nelly Firmin, et al.. (2019). <p>Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?</p>. Cancer Management and Research. Volume 11. 10353–10373. 4 indexed citations

17.

Darlix, Amélie, Pierre‐Jean Lamy, Evelyne Lopez‐Crapez, et al.. (2016). Serum NSE, MMP‐9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?. International Journal of Cancer. 139(10). 2299–2311. 26 indexed citations

18.

Jacot, William, Elvire Pons‐Tostivint, Jean‐Sébastien Frenel, et al.. (2016). Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Research and Treatment. 157(2). 307–318. 79 indexed citations

19.

Darlix, Amélie, Pierre‐Jean Lamy, Evelyne Lopez‐Crapez, et al.. (2016). Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer. 16(1). 428–428. 28 indexed citations

20.

Jacot, William, Nelly Firmin, Lise Roca, et al.. (2016). Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study. Annals of Oncology. 27(7). 1235–1241. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact